E‐cadherin expression is associated with somatostatin analogue response in acromegaly

• Published in: Journal of cellular and molecular medicine Vol. 23; no. 5; pp. 3088 - 3096
• Main Authors: Venegas‐Moreno, Eva, Flores‐Martinez, Alvaro, Dios, Elena, Vazquez‐Borrego, Mari C., Ibañez‐Costa, Alejandro, Madrazo‐Atutxa, Ainara, Japón, Miguel A., Castaño, Justo P., Luque, Raúl M., Cano, David A., Soto‐Moreno, Alfonso
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.05.2019; John Wiley and Sons Inc
• Subjects: acromegaly; Acromegaly - drug therapy; Acromegaly - genetics; Acromegaly - pathology; Adult; Biomarkers - metabolism; Biomarkers, Pharmacological - metabolism; Brain cancer; Cadherins - genetics; E‐cadherin; Female; Gene Expression Regulation - drug effects; Growth Hormone - genetics; Humans; Insulin-Like Growth Factor I - genetics; Male; Middle Aged; Original; Pituitary gland; Pituitary Neoplasms - drug therapy; Pituitary Neoplasms - genetics; Pituitary Neoplasms - pathology; Pituitary Neoplasms - surgery; pituitary tumour; Receptors, Somatostatin - genetics; Somatostatin - administration & dosage; Somatostatin - analogs & derivatives; somatostatin analogues; somatostatin receptor; Tumors; somatostatin receptor; acromegaly; pituitary tumour; somatostatin analogues; E-cadherin
• ISSN: 1582-1838; 1582-4934
• DOI: 10.1111/jcmm.13851

Acromegaly is a rare disease resulting from hypersecretion of growth hormone (GH) and insulin‐like growth factor 1 (IGF1) typically caused by pituitary adenomas, which is associated with increased mortality and morbidity. Somatostatin analogues (SSAs) represent the primary medical therapy for acromegaly and are currently used as first‐line treatment or as second‐line therapy after unsuccessful pituitary surgery. However, a considerable proportion of patients do not adequately respond to SSAs treatment, and therefore, there is an urgent need to identify biomarkers predictors of response to SSAs. The aim of this study was to examine E‐cadherin expression by immunohistochemistry in fifty‐five GH‐producing pituitary tumours and determine the potential association with response to SSAs as well as other clinical and histopathological features. Acromegaly patients with tumours expressing low E‐cadherin levels exhibit a worse response to SSAs. E‐cadherin levels are associated with GH‐producing tumour histological subtypes. Our results indicate that the immunohistochemical detection of E‐cadherin might be useful in categorizing acromegaly patients based on the response to SSAs.